File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Dietary ellagic acid therapy for CNS autoimmunity: Targeting on Alloprevotella rava and propionate metabolism

TitleDietary ellagic acid therapy for CNS autoimmunity: Targeting on Alloprevotella rava and propionate metabolism
Authors
KeywordsAlloprevotella rava
Ellagic acid
Experimental autoimmune encephalomyelitis
Gut microbiota
Multiple sclerosis
Propionate
Issue Date1-Dec-2024
PublisherBioMed Central
Citation
Microbiome, 2024, v. 12, n. 1 How to Cite?
AbstractBackground: Mediterranean diet rich in polyphenolic compounds holds great promise to prevent and alleviate multiple sclerosis (MS), a central nervous system autoimmune disease associated with gut microbiome dysbiosis. Health-promoting effects of natural polyphenols with low bioavailability could be attributed to gut microbiota reconstruction. However, its underlying mechanism of action remains elusive, resulting in rare therapies have proposed for polyphenol-targeted modulation of gut microbiota for the treatment of MS. Results: We found that oral ellagic acid (EA), a natural polyphenol rich in the Mediterranean diet, effectively halted the progression of experimental autoimmune encephalomyelitis (EAE), the animal model of MS, via regulating a microbiota-metabolites-immunity axis. EA remodeled the gut microbiome composition and particularly increased the relative abundances of short-chain fatty acids -producing bacteria like Alloprevotella. Propionate (C3) was most significantly up-regulated by EA, and integrative modeling revealed a strong negative correlation between Alloprevotella or C3 and the pathological symptoms of EAE. Gut microbiota depletion negated the alleviating effects of EA on EAE, whereas oral administration of Alloprevotella rava mimicked the beneficial effects of EA on EAE. Moreover, EA directly promoted Alloprevotella rava (DSM 22548) growth and C3 production in vitro. The cell-free supernatants of Alloprevotella rava co-culture with EA suppressed Th17 differentiation by modulating acetylation in cell models. C3 can alleviate EAE development, and the mechanism may be through inhibiting HDAC activity and up-regulating acetylation thereby reducing inflammatory cytokines secreted by pathogenic Th17 cells. Conclusions: Our study identifies EA as a novel and potentially effective prebiotic for improving MS and other autoimmune diseases via the microbiota-metabolites-immunity axis. 7AEBLBqRMMqqUZLLsSi8h5Video Abstract
Persistent Identifierhttp://hdl.handle.net/10722/358206
ISSN
2023 Impact Factor: 13.8
2023 SCImago Journal Rankings: 3.802
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorHan, Bing-
dc.contributor.authorShi, Lin-
dc.contributor.authorBao, Ming Yue-
dc.contributor.authorYu, Feng Lin-
dc.contributor.authorZhang, Yan-
dc.contributor.authorLu, Xin Yu-
dc.contributor.authorWang, Yang-
dc.contributor.authorLi, Dong Xiao-
dc.contributor.authorLin, Jing Chao-
dc.contributor.authorJia, Wei-
dc.contributor.authorLi, Xing-
dc.contributor.authorZhang, Yuan-
dc.date.accessioned2025-07-26T00:30:21Z-
dc.date.available2025-07-26T00:30:21Z-
dc.date.issued2024-12-01-
dc.identifier.citationMicrobiome, 2024, v. 12, n. 1-
dc.identifier.issn2049-2618-
dc.identifier.urihttp://hdl.handle.net/10722/358206-
dc.description.abstractBackground: Mediterranean diet rich in polyphenolic compounds holds great promise to prevent and alleviate multiple sclerosis (MS), a central nervous system autoimmune disease associated with gut microbiome dysbiosis. Health-promoting effects of natural polyphenols with low bioavailability could be attributed to gut microbiota reconstruction. However, its underlying mechanism of action remains elusive, resulting in rare therapies have proposed for polyphenol-targeted modulation of gut microbiota for the treatment of MS. Results: We found that oral ellagic acid (EA), a natural polyphenol rich in the Mediterranean diet, effectively halted the progression of experimental autoimmune encephalomyelitis (EAE), the animal model of MS, via regulating a microbiota-metabolites-immunity axis. EA remodeled the gut microbiome composition and particularly increased the relative abundances of short-chain fatty acids -producing bacteria like Alloprevotella. Propionate (C3) was most significantly up-regulated by EA, and integrative modeling revealed a strong negative correlation between Alloprevotella or C3 and the pathological symptoms of EAE. Gut microbiota depletion negated the alleviating effects of EA on EAE, whereas oral administration of Alloprevotella rava mimicked the beneficial effects of EA on EAE. Moreover, EA directly promoted Alloprevotella rava (DSM 22548) growth and C3 production in vitro. The cell-free supernatants of Alloprevotella rava co-culture with EA suppressed Th17 differentiation by modulating acetylation in cell models. C3 can alleviate EAE development, and the mechanism may be through inhibiting HDAC activity and up-regulating acetylation thereby reducing inflammatory cytokines secreted by pathogenic Th17 cells. Conclusions: Our study identifies EA as a novel and potentially effective prebiotic for improving MS and other autoimmune diseases via the microbiota-metabolites-immunity axis. 7AEBLBqRMMqqUZLLsSi8h5Video Abstract-
dc.languageeng-
dc.publisherBioMed Central-
dc.relation.ispartofMicrobiome-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectAlloprevotella rava-
dc.subjectEllagic acid-
dc.subjectExperimental autoimmune encephalomyelitis-
dc.subjectGut microbiota-
dc.subjectMultiple sclerosis-
dc.subjectPropionate-
dc.titleDietary ellagic acid therapy for CNS autoimmunity: Targeting on Alloprevotella rava and propionate metabolism -
dc.typeArticle-
dc.identifier.doi10.1186/s40168-024-01819-8-
dc.identifier.pmid38915127-
dc.identifier.scopuseid_2-s2.0-85196646736-
dc.identifier.volume12-
dc.identifier.issue1-
dc.identifier.eissn2049-2618-
dc.identifier.isiWOS:001268362500001-
dc.identifier.issnl2049-2618-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats